BrightGene Bio Medical Technology C (SHG:688166) — Stock Price
BrightGene Bio Medical Technology C (SHG:688166) is currently trading at CN¥34.11 CNY, down 2.54% today. Over the past 52 weeks, shares have ranged between CN¥29.53 and CN¥68.56. This page tracks BrightGene Bio Medical Technology C's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 688166 market cap overview.
BrightGene Bio Medical Technology C (688166) Stock Price Chart — Daily History & Trading Volume
The chart below tracks BrightGene Bio Medical Technology C's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
BrightGene Bio Medical Technology C Income Statement — Revenue, Profit & Earnings by Year
BrightGene Bio Medical Technology C's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥1.28 Billion | CN¥1.18 Billion | CN¥1.02 Billion | CN¥1.05 Billion | CN¥785.38 Million |
| Cost of Revenue | CN¥544.95 Million | CN¥521.41 Million | CN¥376.30 Million | CN¥460.67 Million | CN¥353.99 Million |
| Gross Profit | CN¥737.60 Million | CN¥658.10 Million | CN¥641.03 Million | CN¥591.74 Million | CN¥431.39 Million |
| Research & Development | CN¥297.45 Million | CN¥248.59 Million | CN¥207.02 Million | CN¥173.29 Million | CN¥140.84 Million |
| SG&A | CN¥108.71 Million | CN¥99.70 Million | CN¥123.21 Million | CN¥90.77 Million | CN¥47.49 Million |
| Total Operating Expenses | CN¥1.03 Billion | CN¥925.91 Million | CN¥752.67 Million | CN¥778.01 Million | CN¥577.12 Million |
| Operating Income | CN¥250.83 Million | CN¥253.60 Million | CN¥264.66 Million | CN¥274.40 Million | CN¥208.26 Million |
| EBITDA | — | — | CN¥316.38 Million | CN¥308.65 Million | CN¥223.57 Million |
| EBIT | — | — | CN¥231.38 Million | CN¥249.16 Million | CN¥183.11 Million |
| Interest Expense | CN¥52.44 Million | CN¥44.42 Million | CN¥23.71 Million | CN¥9.70 Million | CN¥2.04 Million |
| Income Before Tax | CN¥157.20 Million | CN¥188.77 Million | CN¥242.21 Million | CN¥257.46 Million | CN¥191.32 Million |
| Income Tax Expense | — | — | CN¥30.78 Million | CN¥19.90 Million | CN¥21.96 Million |
| Net Income | CN¥189.17 Million | CN¥202.47 Million | CN¥239.62 Million | CN¥243.95 Million | CN¥169.88 Million |
BrightGene Bio Medical Technology C Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes BrightGene Bio Medical Technology C's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥5.16 Billion | CN¥5.03 Billion | CN¥4.66 Billion | CN¥2.97 Billion | CN¥1.83 Billion |
| Total Current Assets | CN¥1.64 Billion | CN¥1.84 Billion | CN¥1.94 Billion | CN¥993.01 Million | CN¥946.36 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | CN¥50.62 Million | CN¥50.12 Million | CN¥763.45K | CN¥180.04 Million |
| Net Receivables | CN¥327.78 Million | CN¥282.98 Million | CN¥302.82 Million | CN¥373.35 Million | CN¥177.27 Million |
| Inventory | CN¥364.61 Million | CN¥344.63 Million | CN¥280.35 Million | CN¥200.06 Million | CN¥203.20 Million |
| Property, Plant & Equipment | — | — | CN¥2.08 Billion | CN¥1.38 Billion | CN¥452.50 Million |
| Goodwill | CN¥3.12 Million | CN¥7.50 Million | CN¥7.50 Million | CN¥7.50 Million | — |
| Total Liabilities | CN¥2.73 Billion | CN¥2.61 Billion | CN¥2.42 Billion | CN¥1.23 Billion | CN¥395.23 Million |
| Total Current Liabilities | CN¥1.05 Billion | CN¥922.25 Million | CN¥811.52 Million | CN¥583.07 Million | CN¥291.71 Million |
| Long-term Debt | CN¥1.57 Billion | CN¥1.61 Billion | CN¥1.58 Billion | CN¥618.69 Million | CN¥77.52 Million |
| Net Debt | CN¥915.19 Million | CN¥773.75 Million | CN¥835.26 Million | CN¥565.36 Million | — |
| Total Stockholder Equity | CN¥2.39 Billion | CN¥2.37 Billion | CN¥2.19 Billion | CN¥1.68 Billion | CN¥1.43 Billion |
| Retained Earnings | CN¥960.84 Million | CN¥830.44 Million | CN¥743.35 Million | CN¥555.05 Million | CN¥345.54 Million |
BrightGene Bio Medical Technology C Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how BrightGene Bio Medical Technology C generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥245.56 Million | CN¥194.77 Million | CN¥311.26 Million | CN¥176.08 Million | CN¥155.43 Million |
| Capital Expenditures | CN¥257.20 Million | CN¥389.33 Million | CN¥726.73 Million | CN¥909.66 Million | CN¥355.27 Million |
| Free Cash Flow | CN¥-11.64 Million | CN¥-185.08 Million | CN¥-415.47 Million | CN¥-733.59 Million | CN¥-199.84 Million |
| Investing Cash Flow | — | — | CN¥-871.58 Million | CN¥-889.84 Million | CN¥-541.92 Million |
| Financing Cash Flow | — | — | CN¥1.36 Billion | CN¥703.72 Million | CN¥185.73 Million |
| Dividends Paid | CN¥135.73 Million | CN¥113.75 Million | CN¥100.10 Million | CN¥54.30 Million | CN¥35.40 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥111.41 Million | CN¥78.06 Million | CN¥49.87 Million | CN¥41.50 Million | CN¥30.20 Million |
| Change in Cash | CN¥-216.94 Million | CN¥312.45 Million | CN¥818.52 Million | CN¥-6.32 Million | CN¥-213.79 Million |
BrightGene Bio Medical Technology C Earnings History — EPS Actual vs. Analyst Estimates
Track BrightGene Bio Medical Technology C's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 17, 2025 | — | — | — |
| Apr 24, 2023 | 0.10 | — | — |
| Oct 27, 2022 | 0.21 | — | — |
| Aug 24, 2022 | 0.13 | — | — |
| Apr 27, 2022 | 0.15 | — | — |
| Feb 25, 2022 | 0.16 | — | — |
| Oct 25, 2021 | 0.17 | — | — |
| Aug 24, 2021 | 0.14 | — | — |